|
|
|
|
Treatment with Glecaprevir/Pibrentasvir (G/P)-based regimens of patients with difficult to treat HCV infection. A compassionate use study.
|
|
|
Reported by Jules Levin
AASLD - American Association for the Study of Liver Diseases (AASLD) Congress, October 20-24, 2017, Washington, DC, USA
Victor de Ledinghen, Anne Varaut, Jose Ursic-Bedoya, Jean-Baptiste Hiriart, Giovanna Scoazec, Wassil Merrouche, Georges Philippe Pageaux, Christophe Hezode
Bordeaux - Creteil - Montpellier (France)
|
|
|
|
|
|
|